133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
| Autor: | Davar, D., Knecht, J.G., Vandross, A.L., Perez, C.A., Miller, D.M., Powderly, J., Bessudo, A., Montazeri, K., Mooradian, M.J., Gupta, A., Patel, E., Fantini, D., Paramasivan, S., Crowe, D., Duncan, M., Uptain, S., Luptakova, K., Sullivan, R. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2023 20 Supplement |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|